Gene therapy for cardiovascular disease: perspectives and potential

Area of Science:

• Cardiovascular medicine
• Gene therapy
• Viral vector technology

Background:

• Cardiovascular disease is a leading cause of mortality globally.
• Gene therapy is a frequent approach for cardiovascular diseases, often using adenovirus serotype 5 (Ad5) vectors.
• Systemic Ad5 vector administration faces challenges due to interactions with circulating factors, limiting efficacy.

Purpose of the Study:

• To review the pathogenesis of bypass graft failure and in-stent restenosis.
• To identify potential therapeutic targets for cardiovascular gene therapy.
• To discuss advances in adenovirus biology and vector retargeting for improved cardiovascular applications.

Main Methods:

• Literature review of cardiovascular disease pathogenesis.
• Analysis of current adenovirus vector technology and retargeting strategies.
• Exploration of local gene delivery in the cardiovascular context.

Main Results:

• Bypass graft failure and in-stent restenosis involve complex pathogenic mechanisms.
• Local gene delivery strategies offer potential advantages over systemic administration.
• Adenovirus retargeting research is advancing, aiming to enhance vector specificity and efficacy.

Conclusions:

• Understanding cardiovascular disease pathogenesis is crucial for developing targeted gene therapies.
• Advances in adenovirus biology and retargeting are paving the way for more effective cardiovascular gene therapies.
• Local gene delivery combined with improved adenovirus vectors holds significant promise for treating cardiovascular conditions.